The year 1966 marked a significant evolution in federal drug policy with the passage of the Narcotic Addict Rehabilitation Act (NARA). This legislation fundamentally altered the approach to drug-addicted federal detainees by establishing civil commitment options, representing a notable embrace of a more medical-oriented strategy towards substance abuse.
Prior to this period, federal drug enforcement primarily relied on taxation as a basis for control, with laws like the Harrison Narcotics Act of 1914 focusing on registration and special taxes for certain drugs, leading to the arrest and jailing of many physicians for perceived over-prescribing. However, by the 1960s, there was a discernible shift in attitudes. Support for severe punishment for drug offenses began to wane, with organizations such as the American Bar Association advocating against strict penalties. Simultaneously, federal backing for a medical approach to drug abuse gained momentum, exemplified by the acceptance and increased commonality of methadone maintenance for heroin dependence.
This change in sentiment was solidified by the 1963 Presidential Commission on Narcotic and Drug Abuse. This commission recommended increased funding for narcotic research, less stringent penalties for drug offenses, and even the dismantling of the Federal Bureau of Narcotics (FBN). Congress, indeed, heeded these recommendations.
In line with these evolving perspectives, the Drug Abuse Control Amendments of 1965 had already established the Bureau of Drug Abuse Control (BDAC) within the Department of Health, Education, and Welfare (HEW). While this Act was partly a consumer protection measure regulating commercial pharmaceutical actors, it also saw the creation of an agency within the FDA with armed agents to tackle illicit traffic. Critically, this 1965 legislation also initiated a profound shift in the constitutional authority for federal drug control, moving from the taxing power to the broader power to regulate interstate commerce.
It was against this backdrop that the Narcotic Addict Rehabilitation Act of 1966 was enacted. NARA explicitly declared the policy of Congress that individuals charged with or convicted of federal criminal laws, who were determined to be addicted to narcotic drugs and amenable to rehabilitation, “should, in lieu of prosecution or sentencing, be civilly committed for confinement and treatment designed to effect their restoration to health, and return to society as useful members”. This demonstrated a clear federal commitment to rehabilitation through treatment, providing an alternative to traditional incarceration for eligible individuals.
This move towards treatment and civil commitment in NARA reflects the increasing influence of “addiction medicalizers”—a group composed of health professionals specializing in addiction treatment who largely opposed criminal justice solutions for addiction. This group, despite advocating for forced abstinence in some contexts, fundamentally rejected arrests and jailings, pushing instead for expanded treatment programs. Their efforts, in the late 1960s and early 1970s, successfully prompted both federal and state governments to reallocate funding from punitive measures towards addiction treatment programs. This even led to an expansion of “white markets”—legal pharmaceutical markets—as treatments like methadone became accessible to some, including previously underserved non-white addicted consumers.
However, it is crucial to understand that NARA’s emphasis on treatment did not entirely overshadow the existing strong emphasis on law enforcement during the 1960s. The 1963 Presidential Commission, despite its recommendations for treatment, also advised increasing federal drug enforcement personnel and transferring drug enforcement functions to the Department of Justice (DOJ). This dual approach ultimately led to the 1968 merger of the FBN with the Bureau of Drug Abuse Control, transferring the combined entity to the DOJ. While President Nixon would later, in 1971, officially declare an “all-out offensive” or “War on Drugs” focusing on law enforcement and even cutting treatment budgets, the policies enacted in the mid-1960s, including NARA, laid significant groundwork. These years saw the federal government comprehensively overturn its prior regulatory approach to drugs, establishing a distinction between “white market” pharmaceuticals (regulated as medicines) and “black market” drugs (criminalized substances).
Thus, the 1966 Narcotic Addict Rehabilitation Act stands as a pivotal moment, showcasing a federal effort to integrate a medical and rehabilitative approach into drug policy, driven by evolving public and scientific understanding. Yet, it existed within a complex, often contradictory policy landscape that simultaneously strengthened enforcement mechanisms, setting the stage for the more punitive “War on Drugs” to come.